Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2627-2634

  Housman, Seth T ^a   Pope, J Samuel ^a   Russomanno, John ^a   Salerno, Edward ^a   Shore, Eric ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TEDIZOLID;

ADULT; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; LIQUID CHROMATOGRAPHY; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG FLUID; LUNG FUNCTION; LUNG LAVAGE; MALE; MONTE CARLO METHOD; NAUSEA; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BINDING; STEADY STATE; TANDEM MASS SPECTROMETRY; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; BRONCHOALVEOLAR LAVAGE; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CHROMATOGRAPHY, LIQUID; FEMALE; HALF-LIFE; HUMANS; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; NONTHERAPEUTIC HUMAN EXPERIMENTATION; OXAZOLIDINONES; PRODRUGS; PROTEIN BINDING; PULMONARY ALVEOLI; TANDEM MASS SPECTROMETRY; TETRAZOLES;

EID: 84860148017     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05354-11     Document Type: Article

References (33)

1. Bien P, et al. 2008. Human pharmacokinetics of TR-700 after ascending single oral doses of the prodrug TR-701, a novel oxazolidinone antibiotic, poster F1-2063. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. and the Infect. Dis. Soc. Am. 46th Conf., Washington, DC, 25 to 28 October, 2008. American Society for Microbiology, Washington, DC.
2. Bien P, Prokocimer P, Munoz KA, Bethune C. 2010. Absolute bioavailability of TR-701 FA and pharmacokinetics after single and multiple dose intravenous administration in healthy adult subjects, poster A1-013. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September, 2010. American Society for Microbiology, Washington, DC.
3. Capitano B, et al. 2004. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 125: 965-973. (Pubitemid 38367287)
4. Choi S, Son T, Im W, Rhee J. 2007. In vitro and in vivo antibacterial activity of TR-701 (DA-7218) against penicillin-resistant Streptococcus pneumoniae, poster F1-1689. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17 to 20 September, 2007. American Society for Microbiology, Washington, DC.
5. Conte JE, Jr, Golden JA, Kelley MJ, Zurlinden E. 1995. Intrapulmonary pharmacokinetics of clarithromycin and erythromycin. Antimicrob. Agents Chemother. 39:334 -338.
6. Conte JE, Jr, Golden JA, Kipps J, Zurlinden E. 2002. Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chemother. 46:1475-1480. (Pubitemid 34415331)
7. D'Argenio DZ, Schumitzky A. 1997. ADAPT IIA program for simulation, identification, and optimal experimental design. Biomedical Simulations Resource user manual. University of Southern California, Los Angeles, CA.
8. Drusano GL, Preston SL, Gotfried MH, Danziger LH, Rodvold KA. 2002. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 46:586 -589.
9. File TM. 2003. Community-acquired pneumonia. Lancet 362:1991-2001.
10. Jones RN. 2010. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin. Infect. Dis. 51(Suppl. 1):S81-S87.
11. Jones RN, Moet GJ, Sader HS, Mendes RE, Castanheira M. 2009. TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. J. Antimicrob. Chemother. 63:716-720.
12. Kiem S, Schentag JJ. 2008. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob. Agents Chemother. 52:24 -36.
13. Klevens RM, et al. 2006. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin. Infect. Dis. 42:389 -391.
14. Leary R, Jelliffe R, Schumitzky A, Van Guilder M. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/ PD) models, p 389 -394. In Proceedings of the 14th IEEE Symposium on Computer-Based Medical Systems. IEEE Computer Society, Bethesda, MD.
15. Lemaire S, Van Bambeke F, Appelbaum PC, Tulkens PM. 2009. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J. Antimicrob. Chemother. 64:1035-1043.
16. Liu C, et al. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:e18-e55.
17. Livermore DM, Mustaq S, Warner M, Woodford N. 2009. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J. Antimicrob. Chemother. 63(4):713-715.
18. Lodise TP, et al. 2011. Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrob. Agents Chemother. 55:5507-5511.
19. Lodise TP, Gotfried M, Barriere S, Drusano GL. 2008. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 52:2300 -2304.
20. Olsen KM, et al. 1996. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob. Agents Chemother. 40:2582-2585. (Pubitemid 26367648)
21. Ong CT, Dandekar PK, Sutherland C, Nightingale CH, Nicolau DP. 2005. Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae. Chemotherapy 51:339 -346.
22. Pichereau S, Bohrmuller J, Marchillo K, Stamstad T, Craig W, Andes D. 2009. Comparative pharmacodynamics of a novel oxazolidinone, torezolid phosphate (TR-701), against S. aureus in a neutropenic murine pneumonia infection model, poster A1-1939. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 12 to 15 September, 2009. American Society for Microbiology, Washington, DC.
23. Prokocimer P, et al. 2008. Human pharmacokinetics of the prodrug TR-701 and TR-700, its active moiety, after multiple oral doses of TR-701, a novel oxazolidinone, poster F1-2064. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC, 25 to 28 October, 2008. American Society for Microbiology, Washington, DC.
24. Prokocimer P, et al. 2011. Phase 2, randomized, double-blind, dose ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob. Agents Chemother. 55:583-592.
25. Rennard SI, et al. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as a marker of dilution. J. Appl. Physiol. 60:532-538. (Pubitemid 16019939)
26. Rodvold KA. 1999. Clinical pharmacokinetics of clarithromycin. Clin. Pharmacokinet. 37:385-398.
27. Rodvold KA, Danziger LH, Gotfried MH. 2003. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob. Agents Chemother. 47:2450-2457. (Pubitemid 36919444)
28. Rodvold KA, Gotfried MH, Danziger LH, Servi RJ. 1997. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 41:1399 -1402.
29. Rubinstein E, Cammarata S, Oliphant T, Wunderink R, and Linezolid Nosocomial Pneumonia Study Group. 2001. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 32:402- 412.
30. Schaadt R, Sweeney D, Shinabarger D, Zurenko G. 2009. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob. Agents Chemother. 53:3236 -3239.
31. Shaw KJ, et al. 2008. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents Chemother. 52:4442- 4447.
32. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. 2003. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789 -1797.
33. Yamaoka K, Nakagawa T, Uno T. 1978. Application of Akaike's Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175 (Pubitemid 8384279)